Federal Register / Vol. 70, No. 166 / Monday, August 29, 2005 / Notices 51069 

a recipient address for the shipment of 

KI; 

• Specify the decision-making criteria 

for KI administration; 

• Specify the criteria for issuing KI to 

the public (location, special need); 

• Specify the method for making KI 

available to the public; pre-distribution 

or stockpiling; 

• Specify the method for ensuring the 

supply of KI is sufficient for the targeted 

population, including the estimated 

transient/seasonal population that may 

be advised to take KI; 

• If pre-distributing KI, specify the 

procedure for the public or special 

population groups to obtain KI; 

• Specify the procedure for storing, 

monitoring, safeguarding, dispensing (to 

include, if applicable, tracking who 

received the drug, when, in what 

quantity, and maintenance of waivers 

from liability), and disposing of KI 

stocks; 

• Identify the method for alerting and 

notifying the general public of the 

recommendation to take KI; 

• Specify how the plan is integrated 

into existing emergency response plans; 

and 

• Specify quantities of KI (tablets and 

pediatric liquid oral formulation) that 

will be requested. 

C. Local Governments 

KI requests from local governments 

must certify that: 

• The State in which the local 

government is located does not have a 

DHS-approved KI distribution plan that 

includes KI as a protective measure for 

populations, or a DHS approved plan 

that does not address populations 

located beyond 10 miles from the 

commercial nuclear power plant; 

• The local government has 

petitioned the State in which it is 

located to modify the State plan to 

address populations within 20 miles of 

a commercial nuclear power plant, and 

60 days have elapsed without the State 

modifying the plan to accommodate the 

request; 

• The local government KI plans have 

been approved by the State and certified 

to be ‘not inconsistent’ with the State 

emergency plan; and 

• The local government has reached 

an agreement with the State that the 

State will serve as the single point of 

contact for receipt of KI shipments from 

the stockpile and will then redistribute 

the KI to the approved governments. 

Funding and Resource Requirements 

State, local, and tribal governments 

are responsible for obtaining the 

funding and resources necessary to 

request and implement the KI program 

within their respective jurisdictions, 

should they decide to request KI. Only 

the provision of KI tablets/liquid will be 

funded through HHS. 

Dated: August 24, 2005. 

Robert G. Claypool, 

Deputy Assistant Secretary, Office of Public 

Health Emergency Preparedness, Department 

of Health and Human Services. 

References 

A. NUREG–0654/DHS–REP–1, Criteria for 

Preparation and Evaluation of 

Radiological Emergency Response Plans 

and Preparedness in Support of Nuclear 

Power Plants, March 1987. 

B. NUREG–0396/EPA 520/1–78–016, 

Planning Basis for the Development of 

State and Local Government Radiological 

Emergency Response Plans in Support of 

Light Water Nuclear Power Plants, 

December 1978. 

C. National Academy of Sciences (NAS) 

Study, Distribution and Administration 

of Potassium Iodide in the Event of a 

Nuclear Incident, January 2004. 

D. Federal Emergency Management Agency, 

Notice of revised Federal policy, Federal 

Policy on Use of Potassium Iodide (KI), 

67 FR 1355, January 10, 2002. 

E. Nuclear Regulatory Commission, Final 

rule, Consideration of Potassium Iodide 

in Emergency Plans, 66 FR, 5427, 

January 19, 2001. 

F. World Health Organization, Guidelines for 

Iodine Prophylaxis Following Nuclear 

Accidents, 1999. http://www.who.int/ 

environmentalinformation/ 

Information_resources/documents/ 

Iodine/guide.pdf. 

G. National Council on Radiation Protection 

and Measures (NCRP) Protection of the 

Thyroid Gland in the Event of Releases 

of Radioiodine. NCRP Report No. 55, 

August 1, 1977. 

H. Food and Drug Administration 

(Department of Health and Human 

Services), Potassium Iodide as a ThyroidBlocking Agent in Radiation 

Emergencies; 66 FR 64046, December 11, 

2001. http://www.fda.gov/cder/guidance/ 

4825fnl.htm. 

I. Report of the President’s Commission on 

the Accident at Three Mile Island. 

J. Federal Emergency Management Agency, 

Federal Policy on Distribution of 

Potassium Iodide Around Nuclear Power 

Sites for Use as a Thyroidal Blocking 

Agency, 50 FR, 30258, July 24, 1985. 

K. Nauman, J., and Wolff, J., Iodide 

Prophylaxis in Poland After the 

Chernobyl Reactor Accident: Benefits 

and Risks, American Journal of 

Medicine, Vol. 94, p. 524, May 1993. 

L. International Atomic Energy Agency, 

International Basic Safety Standards for 

Protection Against Ionizing Radiation 

and for Safety of Radiation Sources. 

Safety Series No. 115, 1996. 

M. Food and Drug Administration 

(Department of Health and Human 

Services) Guidance for Industry KI in 

Radiation Emergencies—Questions and 

Answers, http://www.fda.gov/cder/ 

guidance/5386fnl.htm. 

N. Food and Drug Administration 

(Department of Health and Human 

Services) Frequently Asked Questions on 

Potassium Iodide (KI). http:// 

www.fda.gov/cder/drugprepare/ 

KI_Q&A.htm. 

O. Food and Drug Administration 

(Department of Health and Human 

Services) Guidance for Federal Agencies 

and State and Local Governments: 

Potassium Iodide Tablets: Shelf Life 

Extension. http://www.fda.gov/cder/ 

guidance/5666fnl.pdf. 

P. National Council on Radiation Protection 

and Measures (NCRP) Report 138, 

Management of Terrorist Events 

Involving Radioactive Materials. 

[FR Doc. 05–17223 Filed 8–25–05; 2:41 pm] 

BILLING CODE 4150–37–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Statement of Organization, Functions, 

and Delegations of Authority 

Part C (Centers for Disease Control 

and Prevention) of the Statement of 

Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (45 FR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 20, 1980, as amended 

most recently at 70 FR 46527–46530, 

dated August 10, 2005) is amended to 

reflect the establishment of the Office of 

Chief of Public Health Practice within 

the Office of the Director, Centers for 

Disease Control and Prevention. 

After the mission statement for the 

Office of Workforce and Career 

Development (CAL), insert the 

following: 

Office of Chief of Public Health 

Practice (CAR). The Office of Chief of 

Public Health Practice (OCPHP) serves 

as the advocate, guardian, promoter, and 

conscience of public health practice 

throughout CDC and in the larger public 

health community; ensures coordination 

and synergy of CDC’s scientific and 

practice activities; and promotes and 

protects the public’s health through 

science-based, practice-relevant 

standards, policies, and legal tools. 

Activities in support of the mission are 

carried out through programs and 

offices focused on public health law, 

public health system standards, agency 

accreditation, and surveillance for 

emerging issues in public health 

practice. To carry out its mission, 

OCPHP: (1) Develops the legal 

preparedness of CDC programs and the 

public health system to address 

terrorism and other national public 

51070 Federal Register / Vol. 70, No. 166 / Monday, August 29, 2005 / Notices 

health priorities; (2) improves the 

understanding and use of law as a 

public health tool by CDC programs and 

extramural partners; (3) establishes 

robust partnerships among CDC 

programs, public health practitioners 

and key sectors, including elected 

officials, the legal community, and law 

enforcement and emergency response 

organizations; (4) establishes a 

functional area focused specifically on 

standards and improvement in practice 

among state and local public health 

systems; (5) advances the development 

and implementation of a national 

agency accreditation system; (6) relates 

relevant research and policy analysis to 

public health practice; (7) monitors and 

anticipates public health practice trends 

and issues; and (8) coordinates and 

addresses cross-cutting issues related to 

public health practice within CDC. 

Dated: August 10, 2005. 

William H. Gimson, 

Chief Operating Officer, Centers for Disease 

Control and Prevention (CDC). 

[FR Doc. 05–17072 Filed 8–26–05; 8:45 am] 

BILLING CODE 4160–18–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Statement of Organization, Functions, 

and Delegations of Authority 

Part C (Centers for Disease Control 

and Prevention) of the statement of 

Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (45 FR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 20, 1980, as amended 

most recently at 70 FR 46527–46530, 

dated August 10, 2005) is amended to 

reflect the establishment of the 

Coordinating Center for Infectious 

Diseases at the Centers for Disease 

Control and Prevention. 

Section C–B, Organization and 

Functions, is hereby amended as 

follows: 

After the mission statement for the 

Centers for Disease Control and 

Prevention (C), insert the following: 

Coordinating Center for Infectious 

Diseases (CV). The mission of the 

Coordinating Center for Infectious 

Diseases (CCID) is to protect health and 

enhance the potential for full, satisfying 

and productive living across the 

lifespan of all people in all communities 

related to infectious diseases. 

To carry out its mission, CCID: (1) 

Fosters collaborations, partnerships, 

integration, and resource leveraging to 

increase CDC’s health impact and 

achieve population health goals; (2) 

helps investigate and diagnose 

infectious diseases of public health 

significance; (3) coordinates applied and 

operational research to define, prevent, 

and control infectious diseases; (4) 

assists in providing consultation and 

training to help state and local health 

departments plan, develop, implement 

and improve immunization programs; 

(5) coordinates research and operational 

programs to prevent and control 

vaccine-preventable diseases; (6) assists 

in providing technical assistance to 

states, localities, and other nations to 

investigate and diagnose sexually 

transmitted diseases (STDs), 

tuberculosis (TB), human 

immunodeficiency virus (HIV) 

infections, and retroviruses; and 

coordinates applied and operational 

research on the spread, diagnosis, 

prevention and control of HIV, other 

STDs, TB, and non-TB mycobacteria, 

and non-HIV retroviruses. 

Office of the Director (CVA). Manages, 

coordinates, and evaluates the activities 

of the CCID; (2) communicates 

overarching goals and objectives and 

provides leadership, scientific oversight 

and guidance in program planning and 

development; (3) coordinates assistance 

provided by CCID to other CDC 

components, other federal, state, and 

local agencies, the private sector and 

other nations; (4) provides and 

coordinates resource management 

support services for CCID, (e.g., for 

grants, cooperative agreements, and 

other assistance mechanisms); (5) 

coordinates workforce development 

activities within CCID and coordinates 

the recruitment, assignment, technical 

supervision, and career development of 

staff, with emphasis on goals for equal 

employment opportunity and diversity 

where appropriate; (6) assists in the 

development and implementation of a 

comprehensive communication program 

for CCID, assuring that the center’s 

health information is accurately and 

appropriately represented to a diversity 

of constituencies and ensuring 

integration with CDC-wide 

communications activities; (7) provides 

liaison with other governmental 

agencies, international organizations, 

and outside groups representing the 

infectious disease activities of CDC; and, 

(8) collaborates as appropriate with 

other coordinating centers, offices, and 

institutes of CDC, other public health 

service agencies, and other federal 

agencies. 

Dated: August 10, 2005. 

William H. Gimson, 

Chief Operating Officer, Centers for Disease 

Control and Prevention (CDC). 

[FR Doc. 05–17074 Filed 8–26–05; 8:45 am] 

BILLING CODE 4160–18–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Statement of Organization, Functions, 

and Delegations of Authority 

Part C (Centers for Disease Control 

and Prevention) of the statement of 

Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (45 FR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 20, 1980, as amended 

most recently at 70 FR 46527–46530, 

dated August 10, 2005) is amended to 

reflect the establishment of the 

Coordinating Center for Health 

Information and Service at the Centers 

for Disease Control and Prevention. 

Section C–B, Organization and 

Functions, is hereby amended as 

follows: 

After the mission statement for the 

Centers for Disease Control and 

Prevention (C), delete the title 

Coordinating Center for Health 

Information and Service (CP) and insert 

the following: 

Coordinating Center for Health 

Information and Service (CP). The 

mission of the Coordinating Center for 

Health Information and Service (CCHIS) 

is to assure that CDC provides highquality information and programs in the 

most effective ways to help people, 

families, and communities protect their 

health and safety. Through continuous 

consumer input, prevention research, 

and public health information 

technology, we identify and evaluate 

health needs and interests, translate 

science into actions to meet those needs, 

and engage the public in the excitement 

of discovery and the progress being 

made to improve the health of the 

nation. 

In carrying out its mission, the CCHIS 

(1) fosters collaborations, partnerships, 

integration, and resource leveraging to 

increase CDC’s health impact and 

achieve population health goals; (2) 

disseminates and evaluates CDC 

programs and products; (3) manages 

programs, messages to the public, and 

policies in innovative ways; (4) 

monitors, analyzes, and disseminates 

high quality, timely health information